---
title: "Neumora's Alzheimer's Agitation Drug Shows Early Promise"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271542620.md"
description: "Neumora Therapeutics, Inc. (NASDAQ:NMRA) reported promising results from its Phase 1b study of NMRA-511 for Alzheimer's disease agitation, showing a favorable safety profile and clinically meaningful effects. The study indicated significant improvements in agitation scores, with mild to moderate treatment-emergent adverse events. Neumora plans to advance NMRA-511 with further studies and an extended-release formulation by 2026. Additionally, the company will increase enrollment in its KOASTAL studies for major depressive disorder, expecting topline data in Q2 2026. NMRA shares rose 2.11% to $1.69 following the announcement."
datetime: "2026-01-05T16:11:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271542620.md)
  - [en](https://longbridge.com/en/news/271542620.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271542620.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/271542620.md) | [繁體中文](https://longbridge.com/zh-HK/news/271542620.md)


# Neumora's Alzheimer's Agitation Drug Shows Early Promise

**Neumora Therapeutics, Inc.** (NASDAQ:NMRA) on Monday shared results from its Phase 1b signal-seeking study of NMRA-511 for Alzheimer’s disease (AD) agitation.

NMRA-511 demonstrated a clinically meaningful effect size in people with AD agitation.

In the study, NMRA-511 demonstrated a favorable tolerability and safety profile with no reports of somnolence or sedation.

**_Also Read: FDA Fast-Tracks Axsome’s Alzheimer’s Agitation Drug, Stock Soars_**

The Phase 1b study investigated NMRA-511 in healthy elderly adult participants (Part A) as well as people with agitation associated with dementia due to AD (Part B).

## Key Findings

Part B of the Phase 1b study delivered encouraging results.

Patients treated with NMRA-511 demonstrated a -2.6 and -2.1 placebo-adjusted change from baseline on CMAI total score at Weeks 6 and 8, respectively.

Cohen-Mansfield Agitation Inventory (CMAI) is a clinically validated scale measuring the frequency of 29 agitated behaviors.

In the elevated anxiety population, NMRA-511 demonstrated a -7.6 and -5.6 placebo-adjusted change from baseline on CMAI total score at Weeks 6 and 8, respectively.

NMRA-511 demonstrates a favorable tolerability and safety profile. Treatment-emergent adverse events (TEAEs) were typically mild to moderate in severity, and there were low treatment discontinuations due to TEAEs (2.5%).

## Next Steps

Neumora plans to advance NMRA-511 by launching a multiple ascending dose extension study at higher doses in 2026, developing an extended-release formulation to support once-daily dosing in 2026, and initiating a Phase 2/3 dose-ranging study.

On Monday, Neumora also announced that it plans to increase enrollment in each of the KOASTAL studies of navacaprant in major depressive disorder, targeting up to 25% enrollment beyond the original target of 332.

The company expects a joint topline data readout for both KOASTAL-2 and KOASTAL-3 in the second quarter of 2026.

**NMRA Price Action:** Neumora Therapeutics shares were up 2.11% at $1.69 at the time of publication on Monday, according to Benzinga Pro data.

**Read Next:**

-   **L3Harris To Offload Majority Stake In Space Propulsion Businesses For Over $500 Million: Report**

_Photo via Shutterstock_

### Related Stocks

- [Neumora Therapeutics, Inc. (NMRA.US)](https://longbridge.com/en/quote/NMRA.US.md)

## Related News & Research

- [Fosun Pharmaceutical's Subsidiary Gets Nod for Phase I Trial for Breast Cancer Drug](https://longbridge.com/en/news/281480931.md)
- [Is Taysha (TSHA) Recasting Its Rett Strategy With New Market Access Hire After Wider Losses?](https://longbridge.com/en/news/281500622.md)
- [PepGen reports favorable safety and splicing trends for 5 mg/kg cohort, on track for 10 mg/kg readout](https://longbridge.com/en/news/281079324.md)
- [Galderma - Nemolizumab data demonstrate benefits for children moderate-to-severe atopic dermatitis](https://longbridge.com/en/news/280958963.md)
- [UK Regulator OKs Bayer's Treatment for Advanced Non-small Cell Lung Cancer](https://longbridge.com/en/news/281501722.md)